First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Martina LorenziAlessandra FerroFabiana CecereDaniela ScattolinAlessandro Del ConteAlessandro FolladorSara PilottoValentina PoloMariacarmela SantarpiaRita ChiariAlberto PavanAlessandro Dal MasoValentina Da RosGiada TargatoSabrina VariStefano IndraccoloFiorella CalabreseStefano FregaLaura BonannoPier Franco ConteValentina GuarneriGiulia PaselloPublished in: The oncologist (2021)
Osimertinib confirmed effectiveness and safety in the real world, although thromboembolism was more frequent than previously reported.